ZYVERSA THERAPEUTICS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$-513K
R&D
$1M
D&A
$7K
Operating Income
$-25M
EBITDA
$-25M
Other Income/Expense
$-311K
Pretax Income
$-26M
Tax Provision
$-852K
Net Income
$-25M
Operating Margin
4967.3%
Net Margin
4862.0%
Effective Tax Rate
3.3%
Deferred Tax Assets
$4M
Deferred Tax Liabilities
$852K
DTA Valuation Allowance
$21M
NOL Carryforwards
$14M
ETR (Continuing Operations)
3.3%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.4%
Revenue YoY Variation
-90.2%
Income YoY Variation
-179.0%